Chongqing Qiantai Pharmaceutical Research Institute Co., Ltd. (Chongqing Qiantai Biopharmaceutical Co., Ltd.) is a subsidiary of Borui Biopharmaceutical (Suzhou) Co., Ltd., a company listed on the Science and Technology Innovation Board (STAR Market). It focuses on the research, registration, and production of active pharmaceutical ingredients (APIs) for microbial drugs and nano-iron-based APIs. The company has a registered capital of 3 million yuan and fixed assets of more than 15 million yuan. It has an independent research laboratory covering an area of 2,300 square meters. The company has several divisions including strain fermentation, extraction and purification, drug synthesis, drug formulation, drug analysis, drug registration, iron agent R&D, and pharmaceutical information intelligence. The current R&D team consists of more than 80 people, including 20 with master's degrees, 45 with bachelor's degrees, and 8 with college diplomas. The company believes that every employee is a valuable asset for its continuous development, possessing not only rich professional knowledge and strong R&D capabilities but also excellent professional ethics.
Qiantai's products cover the treatment areas of anti-tumor, anti-fungal infections, anti-bacterial drug-resistant infections, and immunosuppressants. Twenty products have been developed and transformed into production, five are being transformed, and more than ten are under research. Products such as Caspofungin and Micafungin have been launched in the domestic market; two technologies have been exported to Europe; over 40 national invention patents have been applied for, with more than 20 authorized; it is a high-tech enterprise in Chongqing, and has been honored with titles such as Chongqing Municipal Enterprise Technology Center and Chongqing Gazelle Enterprise. Qiantai currently has over 80 employees, more than 70 of whom are R&D personnel. Over 20 hold a master's degree or above, and more than 10 have senior professional titles, including one with a senior professional title. The company is equipped with over 300 units (sets) of equipment such as fully automated fermentation tanks, ceramic membranes, ultrafiltration, nanofiltration, freeze dryers, HPLC, UPLC, LC-MS, and GC, which meet the requirements for product development and registration.
The parent company, Bright-Gene Pharmaceutical (Suzhou) Co., Ltd. (Stock Code: 688166), is an innovative pharmaceutical enterprise that participates in international competition. Relying on R&D-driven development, the company focuses on first-to-file, difficult-to-generic, specialty active pharmaceutical ingredients (APIs), complex formulations, and original new drugs. It continuously builds high technological barriers and gradually establishes a business system that integrates APIs and formulations, combines generic and innovative drugs, and gives equal importance to international and domestic markets. The company is committed to addressing the unmet clinical needs of patients worldwide. With the goal of "continuous innovation, safeguarding health," Borui Pharmaceutical provides patients with products of exceptional value. Through years of accumulation, the company has formed several drug technology R&D platforms, including the fermentation semi-synthesis platform, multi-chiral drug platform, non-biological macromolecule platform, drug-device combination platform, and conjugated drug platform. Its products cover areas such as antifungal, antiviral, immunosuppression, antitumor, cardiovascular and cerebrovascular, respiratory, iron supplementation, veterinary drugs, and excipients.
Chongqing Qiantai Pharmaceutical Research Institute Co., Ltd. is committed to benefiting society by producing good medicine for health. With its professional product development capabilities, it provides clients with high-quality products and technical services. The company aims to develop into a competitive, innovative, professional, and high-level drug research and development enterprise under Borui Bio, characterized by a pursuit of excellence.
Stay updated with the latest company news
